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Background/aim: The aim of the study was to evaluate the serum concentration of main chemokines and interferons in patients with
diagnosed endometriosis.
Materials and methods: A total of 160 women were divided in two study groups (group 1 – endometriosis; group 2 – healthy women).
Serum levels of IFN-α, IFN-γ, MCP-1, MIP-1α, MIP-1β, RANTES, eotaxin, IL-8, MIG, IP-10, and IL-17A were measured with Human
Multiplex Cytokine Panels.
Results. Serum levels of IFN-γ, MCP-1, and IL-8 were significantly higher (mean 14.03, 57.24, and 534.24, respectively, compared to
0.58, 20.51, and 259.82, respectively), and serum levels of IP-10 and eotaxin were significantly lower in women with endometriosis
compared to the controls (mean 1.15 and 1.01, respectively, compared to 3.90 and 3.22, respectively).
Conclusions. According to our results women with endometriosis have elevated levels IFN-γ, MCP-1, and IL-8, and lower serum levels
of IP-10 and eotaxin, indicating unbalanced immune activity in endometriosis.
Key words: Chemokine, inflammation, endometriosis, interferon

1. Introduction
Endometriosis is a gynecological condition characterized
by the presence of tissue implants resembling endometrial
glands and stroma in areas outside of the uterus (1). The
ectopic implants are found most commonly in the ovaries
and on the visceral and peritoneal surfaces within the
pelvis. As many as 10% of women aged 30-40 years can
be affected, although many more can have asymptomatic
disease (2). Symptomatic cases have been associated with
deregulated cytokine and chemokine productions in both
ectopic and eutopic endometrium (3,4).
Chemokines are a superfamily of small polypeptides
that induce chemotaxis, activate specific leukocyte
subpopulations in vitro, and regulate leukocyte traffic in
vivo by binding to cell-surface receptors. They have been
classified into two major subfamilies, CXC and CC, based
on the arrangement of the first two of the four conserved
cysteine residues. CXC chemokines are further subdivided
into two classes, ELR and non-ELR, depending on the
presence or absence of a glutamate–leucine–arginine
(ELR) sequence preceding the first two cysteines (5).
Over the last decade, a new protein, interferon-g–
inducible protein-10 (IP-10) or CXCL10, belonging to the
non-ELR CXC chemokine family, has been investigated.
* Correspondence: amalutan@umfcluj.ro

IP-10 expression has been shown to be involved in the
recruitment of lymphocytes in chronic inflammation of
the kidney, liver, and thyroid (5). Endometrial stromal
cells express IP-10 mRNA and secrete its protein. IP-10
protein has been detected in the peritoneal fluid of healthy
women and women with endometriosis; thus it could be
useful as a marker of the disease (5,6).
On the other hand, the immunological balance seems
to be disturbed in endometriosis; therefore, it is useful to
describe the variations in immune factors that contribute
to this imbalance. Interleukin (IL)-8 and other proinflammatory cytokines (IL-1β, IL-6, TNF-α) are factors
considered to play an important role in endometriosis
pathogenesis. It has been shown that concentrations of
IL-8 and TNF-α in the peritoneal fluid are significantly
correlated with the stage of the disease (7–9), but
there is little evidence about serum concentrations of
these cytokines and the severity of the disease. IL-8 is a
macrophage-produced chemokine exhibiting strong
angiogenic, pro-inflammatory, and growth-promoting
effects that induce both chemotaxis of neutrophils
and the expression of several cell adhesion molecules.
The adherence of endometrial cells induces further
IL-8 expression by an integrin-dependent mechanism,
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suggesting that this cytokine might act as an autocrine
growth factor in the pathogenesis of endometriosis
(6,10). IL-8 might also facilitate the initial attachment
of endometrial cells to the peritoneal surfaces because
it stimulates adhesion of endometrial stromal cells to
fibronectin (6,11).
Interferon (IFN)-γ, IP-10, and monocyte chemotactic
protein (MCP)-1 have also been involved in the
pathogenesis of endometriosis; previous studies showed
that IFN-γ and MCP-1 synergistically increase monocyte
activation (12). Elevated levels of MCP-1 in peritoneal fluid
and endometrial glands of endometriosis patients have
been recently reported (12). Thus, a higher concentration
of MCP-1 might be partly responsible for higher IFN-γ
production by monocytes and macrophages.
Given the relationships between the serum
concentration of IFN-gamma, MCP-1, IL-8, IP-10, and
the pathogenesis of endometriosis, our study aimed to
evaluate the serum profile of the main chemokines (IFN-α,
IFN-γ, MCP-1, MIP-1α, MIP-1β, RANTES, eotaxin, IL-8,
MIG, IP-10, and IL-17A) in patients with endometriosis
and their usefulness as specific disease markers.
2. Materials and methods
2.1. Study population and design
We conducted a case-control study that included 160
patients, recruited in consecutive order, divided into two
groups. Group 1 (endometriosis group) contained 80
women with regular menses, and with no history of pelvic
infections, autoimmune and neoplastic diseases who were
undergoing laparoscopy or laparotomy for suspected
endometriosis. The evidence of endometriosis was verified
by histopathological analysis. The severity of endometriosis
was staged according to the revised American Society for
Reproductive Medicine (rASRM) classification. Group
2 (control group) contained 80 healthy nonpregnant
women aged between 18 and 40 years old without clinical
and para-clinical evidence of endometriosis who were
undergoing laparoscopy for unexplained infertility.
Patients with previous pelvic surgeries, history of cancer,
suspected malignancy, adenomyosis or leiomyoma, presurgical suspicion of evidence of premature ovarian
failure, or the use of ovarian suppressive drug, such as oral
contraceptives, GnRH agonists, progestins, or danazol
in the preceding 6 months were excluded from the
study. None of the patients had taken anti-inflammatory
medications or had been diagnosed with an inflammatory
or infectious condition for ≥6 months before the study.
The study protocol was approved by the Local Ethics
Committee of “Iuliu Haţieganu” University of Medicine
and Pharmacy, Cluj-Napoca, Romania, and signed
informed consent was received from each woman before
sample collection. The study was conducted under the
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tenets of the Helsinki Declaration. First 5 mL of venous
blood was collected from each patient before breakfast
and before any surgical procedure, and it was centrifuged
and the serum obtained was stored at –70 °C for future
determinations.
2.2. Cytokine evaluation
We used multiplex cytokine kits (Invitrogen Human
Cytokine 30-Plex Panel, LHC6003) in order to measure
serum levels of IFN-α, IFN-γ, MCP-1 (CCL-2), MIP-1α
(CCL-3), MIP-1β (CCL-4), RANTES (CCL-5), eotaxin
(CCL-11), IL-8 (CXCL8), MIG (CXCL9), IP-10 (CXCL10),
and IL-17A. Measurements were performed with a
Luminex 200 system (Luminex Corporation, Austin, TX,
USA) in accordance with the manufacturer’s specifications
(Invitrogen Corporation, Carlsbad, CA, USA). The
sensitivity of the test was specified by the manufacturer
(Invitrogen Corporation).
Average sensitivity of the test for IFN-α was <5 pg/
mL with an interassay variation coefficient of 7.9%. For
IFN-γ, the average sensitivity of the test was <0.5 pg/
mL, with an interassay variation coefficient of 9.0%. The
average sensitivity of the test for MCP-1 was <5 pg/mL,
with an interassay variation coefficient of 5.8%. In the
case of MIP-1α, the average sensitivity of the test was <5
pg/mL, with an interassay variation coefficient of 9.5%.
The sensitivity of the test for MIP-1β was <5 pg/mL,
and the interassay variation coefficient of 3.6%. The test
for RANTES revealed an average sensitivity of <10 pg/
mL, with an interassay variation coefficient of 8.9%. For
CCL-11, the average sensitivity of the test was <0.5 pg/
mL, with an interassay variation coefficient of 9.0%. In the
case of IL-8, the average sensitivity of the test was <5 pg/
mL, with an interassay variation coefficient of 9.8%. For
MIG, the average sensitivity of the test was <5 pg/mL, with
an interassay variation coefficient of 9.4%. The average
sensitivity of the test for IP-10 was <0.5 pg/mL, with an
interassay variation coefficient of 3.7%, and for IL-17A,
the average sensitivity of the test was <1 pg/mL, with an
interassay variation coefficient of 6.0%.
2.3. Statistical analysis
Statistical analyses were performed using Microsoft
Excel and IBM SPSS software (version 21.0). The data are
presented as mean ± standard deviation (SD) and standard
error (SE) for the groups. The Kolmogorov–Smirnov test
for normality, Levene’s test for equality of variances, and
t-test were used as statistical tests. P values less than 0.05
were regarded as significant.
3. Results
Tables 1–3 present the biometry data, the markers’
distribution among the studied groups, and the detection
rate. Almost all our cases from the endometriosis group
were staged as III (30%–37.50%) or IV (47%–58.75%)
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Table 1. Descriptive statistics of the endometriosis and control groups.
Group

Age (years) (SD)

Weight (kg) (SD)

Height (cm) (SD)

BMI (kg/cm2) (SD)

Endometriosis

30.60 (5.48)

62.05 (9.06)

164.72 (5.11)

22.91 (3.52)

Control

26.35 (2.13)

56.92 (8.09)

167.22 (6.77)

20.30 (2.12)

Average

28.47 (4.65)

59.48 (8.92)

165.97 (6.09)

21.60 (3.17)

SD, Standard deviation; BMI, Body mass index.
Table 2. Descriptive statistics of the studied markers.
Detection rate % (n)

Mean (pg/mL) (SE) ± SD

Skewness (SE)

Kurtosis (SE)

IFN-γ

89.37 (143)

7.31 (2.03) ± 17.27

5.474 (0.28)

36.64 (0.55)

RANTES

99.37 (159)

25.21 (0.171) ± 1.53

–0.372 (0.26)

–0.43 (0.53)

CCL-11

82.5 (132)

2.153 (0.25) ± 2.07

1.957 (0.29)

4.71 (0.58)

MCP-1

95 (152)

37.91 (3.49) ± 30.47

1.804 (0.27)

3.90 (0.54)

IL-8

96.25 (154)

398.81 (63.15) ± 554.19

2.573 (0.27)

6.71 (0.54)

IP-10

76.87 (123)

2.48 (0.37) ± 2.97

2.031 (0.30)

5.12 (0.59)

IL-17

77.5 (124)

1.32 (0.19) ± 1.56

1.641 (0.30)

2.37 (0.59)

SE, Standard error; SD, Standard deviation; IFN, Interferon; RANTES, regulated on activation, normal T
cell expressed and secreted; CCL-11, Eotaxin; MCP, Monocyte chemotactic protein; IL, Interleukin; IP,
Interferon gamma-induced protein.
Table 3. Studied markers group distribution and distribution normality of the studied markers between groups.

Group (n)
IFN-γ
RANTES
CCL-11
MCP-1
IL-8
IP-10
IL-17

Mean (pg/mL) (SE) ± SD

KS with Lilliefors significance correction
Statistic

Probability

E (72)

14.03 (3.76) ± 22.61

0.310

< 0.001

C (71)

0.58 (0.16) ± 0.97

0.230

0.032

E (80)

25.46 (0.22) ± 1.42

0.168

0.200*

C (79)

24.96 (0.25) ± 1.62

0.177

0.200*

E (64)

1.01 (0.14) ± 0.82

0.260

0.005

C (68)

3.22 (0.39) ± 2.31

0.228

0.035

E (72)

57.24 (5.71) ± 34.29

0.159

0.200*

C (80)

20.51 (1.36) ± 8.64

0.148

0.200*

E (78)

534.24 (101.74) ± 635.42

0.333

<0.001

C (76)

259.82 (68.25) ± 420.73

0.115

0.200*

E (63)

1.15 (0.28) ± 1.61

0.257

0.006*

C (60)

3.90 (0.62) ± 3.43

0.362

<0.001*

E (62)

1.41 (0.30) ± 1.70

0.240

0.015

C (62)

1.24 (0.25) ± 1.43

0.237

0.023

*A lower bound of the true significance; E, Endometriosis; C, Control; KS, Kolmogorov–Smirnov; SE, Standard
error; SD, Standard deviation; IFN, Interferon; RANTES, regulated on activation, normal T cell expressed and
secreted; CCL-11, Eotaxin; MCP, Monocyte chemotactic protein; IL, Interleukin; IP, Interferon gamma-induced
protein.
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and only 3 cases (3.75%) were in stage II of endometriosis
according to the rASRM staging criteria. The detection
rate for IFN-α, MIP-1α, MIP-1β, and MIG, respectively, in
the studied groups was 11.25%, 5.0%, 7.5%, and 16.25%,
respectively, without the possibility of establishing
statistical significance. To be able to use parametric tests,
we verified the distribution normality in the studied
groups. Table 3 also presents the obtained data with the
normality test.
Table 4 presents the results obtained with the t-test
for independent samples, which shows that mean serum
levels of IFN-γ, MCP-1, and IL-8 were significantly higher
in patients with endometriosis compared to the healthy
controls (mean 14.03, 57.24, and 534.24, respectively,
compared to 0.58, 20.51, and 259.82, respectively; P = 0.001,
P < 0.001, and P = 0.028, respectively). At the same time
we can observe a significant lower level of CCL-11 and IP10 in patients with endometriosis compared to the healthy
controls (mean 1.01 and 1.15, respectively, compared to
3.22 and 3.90, respectively; P < 0.001, and P < 0.001).
Figures 1–3 show the mean serum levels of the
studied markers between the groups with a significantly
lower serum level of IP-10 and eotaxin (CCL-11), and a
significantly higher serum level of IFN-γ, MCP-1, and
IL-8 in the endometriosis group. No significant differences
were observed in the serum levels of IL-17A and RANTES
between the studied groups.

4. Discussion
Despite the long years of research, the pathophysiology of
endometriosis is still uncertain. A large number of studies
suggest that immune system alterations play critical roles
in the development and progression of endometriosis,
along with hormonal, genetic, and environmental factors.
Our study focused particularly on serum concentration
of IFN-α, IFN-γ, MCP-1, MIP-1α, MIP-1β, RANTES,
eotaxin, IL-8, MIG, IP-10, and IL-17A in patients with
diagnosed endometriosis. We found significantly higher
serum levels of IFN-γ, MCP-1, and IL-8 in women with
endometriosis compared to the healthy controls, and
a significantly lower serum concentration of IP-10 and
eotaxin between the studied groups. We also found that
IL-17A and RANTES had similar serum concentrations
between women with endometriosis and women free
of the disease. On the other hand, IFN-α, MIP-1α, MIP1β, and MIG had a very low detection rate in the studied
groups, and so we were unable to draw any conclusions
regarding their significance.
IFNs are cytokines involved in cellular communication
and immune responses. IFN-γ along with other cytokines
(IL-1, TNF-α) has been previously implicated to play an
important role in the pathogenesis of endometriosis (13).
At the same time, its role in endometriosis is not completely
understood. Some authors have described increased
IFN-γ mRNA expression in endometriosis compared to

Table 4. Statistical significance of the studied markers between the groups.

IFN-γ
RANTES
CCL-11
MCP-1
IL-8
IP-10
IL-17

Equal variances assumed

Levene’s test for
equality of variances

t-test for equality
of means (2-tailed)

0.000

0.001

Equal variances not assumed
Equal variances assumed

0.001*
0.228

Equal variances not assumed
Equal variances assumed

0.152
0.001

Equal variances not assumed
Equal variances assumed

0.000
0.240

Equal variances not assumed

0.029*
0.028

0.002

Equal variances not assumed
Equal variances assumed

0.000
0.000*

Equal variances not assumed
Equal variances assumed

0.000
0.000*

Equal variances not assumed
Equal variances assumed

0.152

0.000
0.000*

0.946

0.680
0.680

* Significant differences; IFN, Interferon; RANTES, regulated on activation, normal T cell expressed
and secreted; CCL-11, Eotaxin; MCP, Monocyte chemotactic protein; IL, Interleukin; IP, Interferon
gamma-induced protein.
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Figure 1. Mean serum levels of eotaxin, IP-10, and IL-17 between the groups.

Figure 2. Mean serum levels of IFN-γ, MCP-1, and RANTES between the groups.

eutopic endometrium (12). It is known that IFN-γ inhibits
the proliferation of human endometrial epithelium (14),
but the resistance of endometriotic cells to IFN-γ-induced
cell growth inhibition and apoptosis has been found to
be a possible mechanism in endometriosis pathogenesis,

and, at the same time, it seems that IFN-γ peritoneal fluid
(PF) levels could be suppressed in endometriosis patients
(15). Different studies have reported contradictory results
regarding peripheral blood (PB) and peritoneal fluid (PF)
concentrations of IFN-γ, with decreases, increases, or
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Figure 3. Mean serum levels of IL-8 between the groups.

lack of differences between women with endometriosis
and controls (5,16,17). Our results are somewhat in
contradiction with the local inhibitory effect of IFN-γ,
as we found an increased level in endometriosis patients
compared with controls, but at the same time INF-γ serum
levels could be influenced by other factors and thus not
a true reflection of the local endometriosis environment.
MCP-1 is a small cytokine belonging to the CC
family. It is secreted by a number of cell types, including
macrophages, endothelial cells, ﬁbroblasts, and mesothelial
and endometrial cells and attracts monocytes, eosinophils,
T lymphocytes, and NK cells (18). Expression of MCP-1 is
induced in human endometrial stromal cells by adhesion
of these cells to extracellular matrix proteins. Recent
studies have found that MCP-1 serum concentration was
signiﬁcantly increased in endometriosis rat models than in
those without, suggesting a possible diagnostic value (18).
On the other hand, PF concentrations of MCP-1 have been
shown to increase with endometriosis severity (19). Our
results are in accordance with those reported by OthmanEel et al. (17), which found increased serum levels of
IFN-γ, MCP-1, and IL-6 in patients with endometriosis
compared to controls, suggesting a possible implication
of these cytokines in endometriosis and also a possible
diagnostic role.
IL-8 is a pro-inﬂammatory chemokine secreted by
several cell types, especially immune cells, with possible
involvement in endometriosis. IL-8, along with other
chemokines, plays important roles in angiogenesis
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associated with endometriosis. Arici et al. reported that
IL-8 is produced in healthy endometrium as well as
in endometriotic tissue and it induces proliferation of
endometrial stromal cells (6). At the same time, Iwabe et
al. demonstrated that IL-8 exerts growth actions in normal
endometrial cells and in endometriotic cells (20). A very
recent review emphasized IL-8 as the best biomarker for
endometriosis, among other chemokines (21). Moreover,
a case-control study showed increased serum levels of IL-8
and IL-6 in patients with ovarian endometriomas (OEs)
(22).
IP-10 is produced by activated lymphocytes, endothelial
cells, ﬁbroblasts, etc., and possesses antiangiogenic
properties. Some authors have shown that IP-10 is also
produced by eutopic endometrial cells (14). At the same
time, different authors have reported significant decreases
in IP-10 PF concentrations in women with advancedstage endometriosis as compared with early-stage disease
(23,24). CCL-11 is a selective chemoattractant for
eosinophils implicated in allergic responses. Hornung et
al. indicated that CCL-11 is produced in epithelial cells of
normal endometrium and endometriosis tissues, varies
across the menstrual cycle, and is elevated in women with
endometriosis (25). Recently, CCL-11 has been implicated
with a critical role in the development of endometriosis
as an angiogenic factor (26). Moreover, another recent
study showed that CCL-11 induced by IL-4 might
promote angiogenesis and the subsequent development of
endometriosis (27).

MĂLUȚAN et al. / Turk J Med Sci
Regarding IL-17A, a very recent study showed
differential expression of IL-17A in human ectopic
endometriotic lesions and matched eutopic endometrium
from women with endometriosis. Moreover, surgical
removal of lesions resulted in significantly reduced plasma
IL-17A concentrations, thus showing that endometriotic
lesions produce IL-17A and that the removal of the lesion
via laparoscopic surgery leads to a significant reduction in
systemic levels of IL-17A (28). Our results show similar
levels between endometriosis patients and controls, thus
adding to the controversy around the role of IL-17A in the
context of endometriosis.
In this context, our results are partially in accordance with
previous studies, showing a decrease in serum concentration
of both IP-10 and CCL-11 and a higher level of IL-8. These
results are obtained in cases of advanced endometriosis, most
of the patients presenting for large OEs suggesting a possible
correlation between PF concentrations and serum levels of
IL-8 and IP-10 as in the study conducted by Yoshino et al.,
and also confirming the findings reported by Carmona et al.
Limitations of the present study could arise from the
study population. On one hand, patients included in the
study were only Caucasian women. Most of the literature
studies had mainly Asian origin subjects, this being
considered a possible bias mark. On the other hand, most
of the patients included in our study were stage III or IV. As
the study was conducted in a university clinic, the patients
presenting for treatment and included in the study had late
stages of endometriosis, thus the low rate of early stages.
Probably future studies could include patients presenting
for unexplained infertility undergoing laparoscopy, thus

including patients with early stages discovered incidentally.
We could also take in consideration as a limitation the
detection sensitivity of multiplexed immunoassays. It
was shown that while multiplexed immunoassays have
sensitivity comparable to conventional ELISA, it is possible
that the robustness may vary among different multiplex
bead arrays (29).
In conclusion, the present study evaluated the possible
differences in main chemokines serum concentration from
patients with endometriosis compared to healthy controls
using a multiplexed cytokine assay. We have shown that
chemokines with a pro-inflammatory profile, IL-8, MCP-1,
and IFN-γ have significantly higher serum levels in women
with endometriosis compared to controls, and that eotaxin
and IP-10, a chemokine secreted in response to IFN, have
significantly lower levels in women with endometriosis
compared to women free of disease. No difference was
found in the serum levels of IL-17A and RANTES between
the groups. All of these changes, associated with changes
in cytokine profile, indicate an unbalanced immune
activity in endometriosis, which could be responsible for
the occurrence and progression of the disease. Further
studies are necessary to conﬁrm the involvement of these
chemokines in the pathogenesis of endometriosis, and
moreover to establish their possible role in diagnosis or
treatment of endometriosis.
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